{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:58:53Z","timestamp":1770512333053,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.anai.2016.10.028","type":"journal-article","created":{"date-parts":[[2016,12,4]],"date-time":"2016-12-04T21:30:56Z","timestamp":1480887056000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis"],"prefix":"10.1016","volume":"118","author":[{"given":"Melanie D.","family":"Whittington","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Brett","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.10.028_bib1","unstructured":"Centers for Disease Control and Prevention. Asthma Facts-National Asthma Control Program Grantees. 2013. www.cdc.gov\/asthma\/pdfs\/asthma_facts_program_grantees.pdf. Accessed January 21, 2016."},{"key":"10.1016\/j.anai.2016.10.028_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.anai.2016.10.028_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-014-0213-9","article-title":"Defining phenotypes in asthma: a step towards personalized medicine","volume":"74","author":"Chung","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2016.10.028_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2016.10.028_bib5","unstructured":"GlaxoSmithKline. Nucala Full Prescribing Information. 2015. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL.PDF. Accessed December 10, 2015."},{"key":"10.1016\/j.anai.2016.10.028_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.10.028_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.anai.2016.10.028_bib8","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1513\/AnnalsATS.201309-295RM","article-title":"The \u201ce\u201d in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence","volume":"11","author":"Campbell","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.anai.2016.10.028_bib9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1398-9995.2010.02336.x","article-title":"The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective","volume":"65","author":"Campbell","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.10.028_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1398-9995.2008.01723.x","article-title":"An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma","volume":"63","author":"Sullivan","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.10.028_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jval.2014.07.009","article-title":"Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis","volume":"17","author":"Faria","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.anai.2016.10.028_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17520","article-title":"Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation","volume":"17","author":"Norman","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.anai.2016.10.028_bib13","series-title":"Omalizumab for Treating Severe Persistent Allergic Asthma","author":"National Institute for Clinical Excellence","year":"2013"},{"key":"10.1016\/j.anai.2016.10.028_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2016.10.028_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1183\/09031936.00124209","article-title":"Long-acting \u03b22-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD","volume":"36","author":"de Vries","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2016.10.028_bib16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.rmed.2007.03.006","article-title":"Factors associated with mortality after an asthma admission: a national United Kingdom database analysis","volume":"101","author":"Watson","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2016.10.028_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","article-title":"The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK","volume":"16","author":"Lloyd","year":"2007","journal-title":"Primary Care Respir J"},{"key":"10.1016\/j.anai.2016.10.028_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/14737167.2015.978292","article-title":"Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma","volume":"15","author":"Cangelosi","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.anai.2016.10.028_bib19","unstructured":"Redbook Online [online database]. Greenwood Village, CO: Truven Health Analytics. Accessed October 28, 2015."},{"key":"10.1016\/j.anai.2016.10.028_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clinthera.2013.03.001","article-title":"Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Therap"},{"key":"10.1016\/j.anai.2016.10.028_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jval.2010.09.011","article-title":"Predicting EQ-5D values using the SGRQ","volume":"14","author":"Starkie","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.anai.2016.10.028_bib22","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s11136-016-1357-8","article-title":"Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes","volume":"25","author":"Sullivan","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.anai.2016.10.028_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.10.028_bib24","unstructured":"Anthem Blue Cross. Mepolizumab (Nucala\u00ae). https:\/\/www.anthem.com\/ca\/medicalpolicies\/policies\/mp_pw_c184800.htm. Accessed January 21,\u00a02016."},{"key":"10.1016\/j.anai.2016.10.028_bib25","unstructured":"Humana. Medical and pharmacy coverage policies. http:\/\/apps.humana.com\/tad\/tad_new\/home.aspx?type=provider. Accessed January 21,\u00a02016."},{"key":"10.1016\/j.anai.2016.10.028_bib26","unstructured":"Aetna. Specialty pharmacy clinical policy bulletins Aetna non-Medicare prescription drug plan (Nucala). http:\/\/www.aetna.com\/products\/rxnonmedicare\/data\/2015\/RESP\/Interleukin%20Antagonist.html. Accessed January 21,\u00a02016."}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616312674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616312674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:16:56Z","timestamp":1761052616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616312674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1081120616312674"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.10.028","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}